Shibing Wang
5 Papers
4 Citations
Shibing Wang is an academic researcher. The author has contributed to research in topics: Cancer & Myeloid leukemia. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Molecular Imaging of Cancer with Nanoparticle-Based Theranostic Probes
TL;DR: The achievements of modern nanoparticles with the goal of accurate tumor imaging and effective treatment are discussed and the future prospects of the resulting nanosystem are discussed.
Synergistic suppression effect on tumor growth of ovarian cancer by combining cisplatin with a manganese superoxide dismutase-armed oncolytic adenovirus.
Shibing Wang,Jing Shu,Li Chen,Xiaopan Chen,Jianhong Zhao,Shuangshuang Li,Xiaozhou Mou,Xiangmin Tong +7 more
TL;DR: It is demonstrated that ZD55-MnSOD can sensitize human ovarian cancer cells to cisplatin-induced cell death and apoptosis in vitro and in vivo and indicate that the combined treatment with ZD 55-manganese superoxide dismutase and cis Platin could represent a rational approach for antiovarian cancer therapy.
Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients
TL;DR: It was established that CAR exerted complex effects during liver tumorigenesis, potentially based on the stage of the cancer, and CAR expression analysis has to be carried out prior to adenoviral oncolytic therapy to stratify the patients.
Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus.
Jiamin Peng,Shibing Wang,Weimin Fan,Shuangshuang Li,Yi Wu,Xiao-Zhou Mou,Jianchao Wang,Xiangmin Tong +7 more
TL;DR: Wang et al. as mentioned in this paper proposed a new oncolytic vaccinia virus (oVV-ING4), which expresses the inhibitor of growth family member 4 (ING4) and explored its antitumor activity individually and in combination with cytarabine in AML cells.
Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway.
Yue-Xing Tu,Shibing Wang,Luo-Qin Fu,Shuangshuang Li,Qian-Peng Guo,Yi Wu,Xiao-Zhou Mou,Xiangmin Tong +7 more
TL;DR: Results demonstrate the PI3K/AKT/mTOR signaling-mediated anti-hCSC effect of Ova in CML, as well as suggest a likely role for Ova as a small molecule PI3k/ mTOR dual inhibitor, thus, extending its potential benefit to other mTOR-mediated pathologies.